Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter

Cancer Research

Volumn 62, Issue 16, 2002, Pages 4663-4670

  Nettelbeck, Dirk M ^a   Rivera, Angel A ^a   Balagué, Cristina ^a   Alemany, Ramon ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOPHENOL MONOOXYGENASE; ONCOLYTIC VIRUS; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; CELL CYCLE; CYTOLYSIS; CYTOTOXICITY; GENE MUTATION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS REPLICATION;

ADENOVIRUS E1A PROTEINS; ADENOVIRUSES, HUMAN; COCULTURE TECHNIQUES; CYTOPATHOGENIC EFFECT, VIRAL; HUMANS; KERATINOCYTES; MELANOMA; MONOPHENOL MONOOXYGENASE; PROMOTER REGIONS (GENETICS); RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0037102156     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. The current management of cutaneous melanoma
2. Current therapy for cutaneous melanoma
3. Gene therapy for cancer
4. Development and application of adenoviral vectors for gene therapy of cancer
5. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
6. The development of conditionally replicative adenoviruses for cancer therapy
7. Replicative adenoviruses for cancer therapy
8. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells
9. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
10. Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
11. Cyclins and cyclin-dependent kinases: Take your partners
12. A simplified system for generating recombinant adenoviruses
13. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control
14. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo
15. Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for virus growth in vivo
16. Cellular targets for transformation by the adenovirus E1A proteins
17. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
18. Evaluation of El-mutant adenoviruses as conditionally replicating agents for cancer therapy
19. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction
20. Melanogenesis: A realistic target for antimelanoma therapy?
21. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
22. In vitro and in vivo targeting of gene expression to melanoma cells
23. Gene therapy: Designer promoters for tumour targeting
24. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
25. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging
26. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
27. Absence of p53 gene mutations in cutaneous melanoma
28. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
29. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy
30. Human papillomavirus e6e7-mediated adenovirus cell killing: Selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes
31. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter
32. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector
33. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors
34. Insulation of a conditionally expressed transgene in an adenoviral vector
35. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo
36. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
37. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
38. Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication
39. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters
40. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
41. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
42. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
43. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy
44. Immunotherapy of melanoma
45. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
46. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxombicin
47. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures
48. Genetic targeting of adenoviral vectors
49. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105)